Innovating for Success
Citius is developing novel formulations of previously approved pharmaceutical products to seek new and expanded indications, and achieve improved market positioning or market exclusivity.
Combination Therapy for GI Disorder
Citius is developing a two drug combination product for the treatment of hemorrhoids. By age 50, about half of adults will have suffered from the pain, bleeding, itching and discomfort caused by this condition.
Citius is a specialty pharmaceutical company developing and commercializing therapeutic products for large and growing markets. Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market positioning or market exclusivity.
Suprenza, Citius’ first FDA-approved product, is a novel formulation of a leading obesity drug. Citius’ is also advancing a product candidate for the treatment of hemorrhoids, a common gastrointestinal condition.
Treatment of GI Disorder
Citius intends to develop a topical formulation containing hydrocortisone and lidocaine to provide anti-inflammatory and anesthetic relief to patients suffering from hemorrhoids. Citius believes its therapy will become an important treatment option for physicians who want to provide their patients with a therapy that has demonstrated safety and efficacy.